Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Working Capital Changes (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Other Working Capital Changes for 10 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 1395.58% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.3 million, a N/A change, with the full-year FY2025 number at $6.3 million, changed N/A from a year prior.
  • Other Working Capital Changes was $2.7 million for Q4 2025 at Rhythm Pharmaceuticals, down from $4.9 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $4.9 million in Q4 2021 to a low of -$3.0 million in Q3 2021.
  • A 5-year average of $474736.8 and a median of -$6000.0 in 2023 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: crashed 294.92% in 2021, then soared 40450.0% in 2024.
  • Rhythm Pharmaceuticals' Other Working Capital Changes stood at $4.9 million in 2021, then crashed by 53.18% to $2.3 million in 2022, then tumbled by 208.97% to -$2.5 million in 2023, then skyrocketed by 107.2% to $181000.0 in 2024, then surged by 1395.58% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Other Working Capital Changes are $2.7 million (Q4 2025), $4.9 million (Q3 2025), and -$1.3 million (Q1 2025).